Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Current Deferred Revenue (2018 - 2022)

Ani Pharmaceuticals (ANIP) has disclosed Current Deferred Revenue for 8 consecutive years, with $116000.0 as the latest value for Q1 2022.

  • Quarterly Current Deferred Revenue rose 16.0% to $116000.0 in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $116000.0 through Mar 2022, up 16.0% year-over-year, with the annual reading at $87000.0 for FY2021, 13.0% down from the prior year.
  • Current Deferred Revenue hit $116000.0 in Q1 2022 for Ani Pharmaceuticals, up from $87000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $735000.0 in Q3 2018 to a low of $87000.0 in Q4 2021.
  • Historically, Current Deferred Revenue has averaged $318800.0 across 5 years, with a median of $125000.0 in 2020.
  • Biggest five-year swings in Current Deferred Revenue: crashed 80.0% in 2020 and later rose 16.0% in 2022.
  • Year by year, Current Deferred Revenue stood at $711000.0 in 2018, then fell by 29.68% to $500000.0 in 2019, then plummeted by 80.0% to $100000.0 in 2020, then decreased by 13.0% to $87000.0 in 2021, then skyrocketed by 33.33% to $116000.0 in 2022.
  • Business Quant data shows Current Deferred Revenue for ANIP at $116000.0 in Q1 2022, $87000.0 in Q4 2021, and $100000.0 in Q3 2021.